The article reviews various targeted therapeutic strategies to overcome resistance in cancer treatment. It discusses the use of drug combinations and dual inhibitors as promising alternatives to current treatments like chemotherapy, radiotherapy, and immunotherapy. The review covers different vectorization platforms, including liposomes, polymeric nanoparticles, micelles, dendrimers, carbon nanotubes, and antibody-drug conjugates (ADCs), each with its unique advantages and mechanisms of drug release. The effectiveness of these platforms in enhancing cancer treatment is evaluated, highlighting their ability to target cancer cells specifically and minimize side effects. The article also explores multitarget therapies, such as combination therapies and dual inhibitors, which can reduce the need for multiple drugs and minimize resistance. Examples of successful drug combinations and dual inhibitors in solid tumors like breast, colorectal, prostate, and lung cancer are provided, demonstrating their efficacy in improving patient outcomes. The review concludes by emphasizing the ongoing challenges and future directions in cancer therapy, particularly in addressing resistance and improving quality of life for patients.The article reviews various targeted therapeutic strategies to overcome resistance in cancer treatment. It discusses the use of drug combinations and dual inhibitors as promising alternatives to current treatments like chemotherapy, radiotherapy, and immunotherapy. The review covers different vectorization platforms, including liposomes, polymeric nanoparticles, micelles, dendrimers, carbon nanotubes, and antibody-drug conjugates (ADCs), each with its unique advantages and mechanisms of drug release. The effectiveness of these platforms in enhancing cancer treatment is evaluated, highlighting their ability to target cancer cells specifically and minimize side effects. The article also explores multitarget therapies, such as combination therapies and dual inhibitors, which can reduce the need for multiple drugs and minimize resistance. Examples of successful drug combinations and dual inhibitors in solid tumors like breast, colorectal, prostate, and lung cancer are provided, demonstrating their efficacy in improving patient outcomes. The review concludes by emphasizing the ongoing challenges and future directions in cancer therapy, particularly in addressing resistance and improving quality of life for patients.